Thyroid cancer biomarker ID'd

A team of researchers has discovered a new biomarker that can be used to identify aggressive thyroid cancer and predict outcomes for patients. "Our study shows, for the first time, a key biomarker that can be used in diagnostic, prognostic and therapeutic strategies for the future management of thyroid cancer," said endocrinologist Paul Walfish, Alex and Simona Shnaider Research Chair in Thyroid Oncology at Mount Sinai Hospital and the senior author of the study. Story

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.